secwatch / observer
8-K filed June 16, 2026, 4:06 PM ET ticker PBYI CIK 0001401667
other material confidence high sentiment negative materiality 0.15

Puma shareholders reject CEO Auerbach's warrant extension to Oct 2028

PUMA BIOTECHNOLOGY, INC.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

PUMA BIOTECHNOLOGY, INC. shareholders rejected Amendment to warrant terms to extend expiration at the 2026-06-11 meeting.

Outcome
failed
Meeting
2026-06-11
Exact text from the filing
Proposal 4: The Company’s stockholders did not approve an amendment to the terms of the warrant, issued to Alan H. Auerbach, President and Chief Executive Officer of the Company on October 4, 2011, as amended on June 15, 2021, to purchase 2,116,250 shares of the Company’s common stock at $16.00 per share (the “Auerbach Warrant”), to extend the term of the Auerbach Warrant from October 4, 2026 until October 4, 2028. For Against Abstain Broker Non-Votes 18,234,150 19,596,238 85,914 0
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

PUMA BIOTECHNOLOGY, INC. shareholders approved Ratification of KPMG LLP as independent auditor at the 2026-06-11 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-06-11
Exact text from the filing
Proposal 2: The Company’s stockholders ratified the selection of KPMG LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2026. For Against Abstain Broker Non-Votes 42,612,940 1,328,476 39,599 0
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

PUMA BIOTECHNOLOGY, INC. shareholders approved Election of eight directors at the 2026-06-11 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-06-11
Exact text from the filing
Proposal 1: The Company’s stockholders elected the eight nominated directors identified below, each to serve and to hold office for a one-year term until the close of the Company’s next annual meeting of stockholders in 2027 and until their successors have been duly elected and qualified or until their earlier resignation or removal. Nominee For Withheld Broker Non-Votes Alan H. Auerbach 37,130,678 785,624 6,064,713 Alessandra Cesano 37,472,173 444,129 6,064,713 Allison Dorval 37,447,432 468,870 6,064,713 Michael P. Miller 37,220,974 695,328 6,064,713 Jay M. Moyes 36,586,798 1,329,504 6,064,713 Adrian M. Senderowicz 37,217,253 699,049 6,064,713 Brian Stuglik 37,372,588 543,714 6,064,713 Troy E. Wilson 32,546,955 5,369,347 6,064,713
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

PUMA BIOTECHNOLOGY, INC. shareholders approved Advisory vote on executive compensation at the 2026-06-11 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2026-06-11
Exact text from the filing
Proposal 3: The Company’s stockholders voted to approve, on an advisory basis, the compensation of the Company’s named executive officers. For Against Abstain Broker Non-Votes 29,326,673 7,878,580 711,049 0
View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

PUMA BIOTECHNOLOGY, INC. filing history →

Source: SEC EDGAR
accession 0001437749-26-020793
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.